ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

GENF Genflow Biosciences Plc

2.20
0.15 (7.32%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genflow Biosciences Plc LSE:GENF London Ordinary Share GB00BP2C3V08 ORD GBP0.0003
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.15 7.32% 2.20 2.10 2.30 2.20 2.05 2.05 729,631 13:13:56
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 169k -1.63M -0.0047 -4.68 7.17M
Genflow Biosciences Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENF. The last closing price for Genflow Biosciences was 2.05p. Over the last year, Genflow Biosciences shares have traded in a share price range of 1.35p to 3.30p.

Genflow Biosciences currently has 349,706,618 shares in issue. The market capitalisation of Genflow Biosciences is £7.17 million. Genflow Biosciences has a price to earnings ratio (PE ratio) of -4.68.

Genflow Biosciences Share Discussion Threads

Showing 1176 to 1200 of 1300 messages
Chat Pages: 52  51  50  49  48  47  46  45  44  43  42  41  Older
DateSubjectAuthorDiscuss
17/5/2024
07:17
Would be great to see another rise today. Big positions still being taking. Free float is dry. Rerate happening
northeast14
16/5/2024
21:25
Genflow's collaborative partner for the delivery of SIRT6 and key to advancing the GMP manufacturing of its lead drug candidate. Gla :-)

18/4/24

"EXO Biologics recently created ExoXpert as an exosome CDMO to meet the demand for specialized GMP grade exosome manufacturing services internationally. As a therapeutic exosome developer, this was something EXO Biologics needed, but we also realized the international market needed this as well," said Hugues Wallemacq, CEO, ExoXpert and EXO Biologics. "ExoXpert has started working with a significant number of international cell and gene therapy developers that need a combination of exosome manufacturing and knowledge to develop new products for the benefit of patients. Partnering with Neucore will enable ExoXpert to further extend ExoXpert’s expertise in loading exosomes to Neucore’s FiXE platform.”

moneymunch
16/5/2024
21:16
7/5/24

Outlook for 2024



Our key objectives for 2024 are:



· Continuing to identify suitable grant funding to support the Group's project pipeline.

· Undertake key Investigational New Drug (IND)-enabling development activities that will help define the pharmacological and toxicological properties of our lead drug candidate, GF-1002, and its potential benefits for MASH patients.

· Select site and QMS framework for clinical readiness, expected by the end of 2025 for the MASH program.

· Commence preliminary discussions with the European Medicines Agency (EMA) on Mechanism of Action (MoA) data for Orphan Drug Application (ODA) for our second compound GF-3001, targeting Werner Syndrome.

· Select Contract Development and Manufacturing Organization (CDMO) for advancing the GMP manufacturing of the MASH clinical lot of lead drug candidate, GF-1002.

· Develop and implement project management, budgeting and governance for collaborative partners, in line with clinical and pre-clinal activities that will enable IND applications.

· Move key patent applications under the Patent Cooperation Treaty (PCT) to the national phase, while further expanding our development pipeline with new products and new indications.

moneymunch
16/5/2024
19:24
Must be news coming, certainly lots of big news that could drop at any time 👍🙏👍
steg
16/5/2024
18:10
Great day!
northeast14
16/5/2024
16:48
We could open above 2.4p at this rate. Gla holders...Excitement building;-)))
moneymunch
16/5/2024
16:44
Encouraging action late-on, but I won't be getting excited until we close above 2.4p... GLA
cyberbub
16/5/2024
15:54
Got a feeling the free float has been mopped UP!!! :-)
moneymunch
16/5/2024
15:46
Good news could drop at anytime to add significant value, but "The first payment of €777,000 from the 2.89m Euros grant is due to be received imminently" as stated in last week's results and confirmed in today's LinkedIn post...and so confirmation should be very well received. Gla...On and UP!!!:-)
moneymunch
16/5/2024
15:37
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,606 followers
3h

The #biotech space has continued to out perform expectations. As the industry is teetering on another market rally, many companies have had exciting developments.

Regeneron, for one, has announced it successfully restored the hearing of two children experiencing otoferlin hearing loss.

Additionally, Genflow Biosciences (LON:GENF) (OTCQB:GENFF) has secured several significant grants, some of whose payment is expected imminently. These will help advance its #sarcopenia & #mRNA delivery research.

Learn about Genflow's exciting investment proposition:

#pharma #aging #GENF

moneymunch
15/5/2024
22:34
Ditto Northeast, the free float is getting tighter and tighter and so every chance of a decent move North as more buyers arrive in anticipation of the next UPdate or two. Gl :-)
moneymunch
15/5/2024
20:39
Money, the endless cheap shares can’t go on for ever. Looking forward to seeing more movement very soon
northeast14
15/5/2024
09:05
Momentum building with the majority of shares very tightly held!!! Gla holders...On and UP!!! :-)
moneymunch
14/5/2024
20:38
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,604 followers

8h

The #biotech space is cluttered with many companies claiming to be on the cutting edge, with little to back this up. Genflow Biosciences (LON:GENF) (OTCQB:GENFF), on the other hand, stands out in numerous ways.

Differentiating between the true innovators and the rest can be difficult. That's why we've created a new fact sheet summarizing our exciting research that aims to extend both human and canine #healthspan.

What sets #GENF apart:
✅ Long life IP, protecting our #SIRT6 cenenarian gene & gene delivery research
✅ Creating #NASH treatment to address untapped market of 35 million people
✅ Lead by experienced team with a background running public companies

Learn more about Genflow's exciting investment thesis:

moneymunch
14/5/2024
16:40
Hopefully the unjustified drop is over with now. Someone was very lucky with some cheap shares.
northeast14
14/5/2024
15:56
This has certainly required some patience but it looks as though things are starting to get under way at last. Interest appears to be building. GLA
felchandbart
14/5/2024
15:16
Bid jumped to 1.95 with no buys showing to justify….yet 👍
steg
14/5/2024
14:53
Another 1m plus mopped UP!!! Gla :-)
moneymunch
14/5/2024
11:10
Lol, a pause in proceedings, £25k plus bought yesterday, £30k Friday, £40k Thursday along with confirmation Mr Swann is accumulating more and he's not the only one who is planning to buy more I reckon. Gl :
moneymunch
14/5/2024
10:32
GBP200 traded this morning so far...
cyberbub
14/5/2024
07:47
Anytime soon Northeast, although I'd prefer the share price to be firmly above 2p and more before the next UPdate arrives, which will be more than likely in the coming days as the share accumulation continues. Gl :-)
moneymunch
14/5/2024
07:29
Was hoping for an update. Hopefully there is one soon
northeast14
13/5/2024
11:05
A 1m buy just been filled. Gla :-)
moneymunch
10/5/2024
20:52
Looks like a 2m plus late reported buy imho...Gla ;-)
moneymunch
10/5/2024
11:59
Mr Swann is adding more...the smart Money is accumulating. Gla holders On and UP!!! :-)
moneymunch
Chat Pages: 52  51  50  49  48  47  46  45  44  43  42  41  Older